// App-Quantinova.ai

CT303 : The effect of savolitinib plus osimertinib on ctDNA clearance in patients with EGFR mutation positive (EGFRm) MET-amplified NSCLC in the TATTON study

Researchers

Presenter

  • Ryan Hartmaier

Principal Investigators

  • Ji-Youn Han

  • Myung-Ju Ahn

  • Byoung Chul Cho

  • Mireille Cantarini

  • Paul Frewer

  • Melanie M. Frigault

  • Geoffrey Oxnard

Medical Centers

  • AstraZeneca, Boston, MA

  • National Cancer Center, Goyang, Republic of Korea

  • Samsung Medical Center, Seoul, Republic of Korea

  • Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of (South)

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

  • Republic of South Korea

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Circulating DNA

  • Threonine at amino acid position 790

Drug/Treatment

  • Savolitinib

  • Tagrisso

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I

Study Id's

  • NCT02143466

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved